Evinacumab

Regeneron announced the FDA has approved evinacumab for treatment of patients aged 12 years or older with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering therapies.

Evinacumab, a novel fully human monoclonal antibody against angiopoietin-like 3, reduced LDL by more than 50% compared with placebo in patients with refractory hypercholesterolemia, researchers reported.